Backed by Medicxi, No­var­tis vets launch rare blood dis­or­der biotech with fresh take on drug class used in can­cers

In 2017, two No­var­tis clin­i­cians — Pierre Saint-Mezard and Damien Pi­card — ap­proached Nicholas Bene­dict, who’d left No­var­tis in 2007 and went on to head a se­ries …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER